NCT00111774View on ClinicalTrials.gov

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2002

Conditions
Colorectal CancerCarcinoma
Interventions
DRUG

ABX-EGF

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00111774 - Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma | Biotech Hunter | Biotech Hunter